OrbiMed’s Boston Scientific BSX Stock Holding History

OrbiMed’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-200,000	Closed	-$19.5M	–	114
2025 Q3	$19.5M	Buy	+200,000	New	+$20.7M	0.46%	54
2021 Q3	–	Sell	-250,000	Closed	-$10.7M	–	177
2021 Q2	$10.7M	Buy	+250,000	New	+$10.5M	0.11%	123
2019 Q1	–	Sell	-250,000	Closed	-$8.84M	–	129
2018 Q4	$8.84M	Buy	+250,000	New	+$9.07M	0.16%	90

Other funds holding BSX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

OrbiMed's BSX Position: Q1 2026 in Review

OrbiMed reduced its Boston Scientific (BSX) stake by 1.5% in Q1 2026, selling an estimated $2.98M and leaving 2,382,100 shares worth $149M. The position accounts for 2.96% of the portfolio, ranked #7.

OrbiMed first reported a position in BSX in Q3 2013 and has held it in 50 quarters since. The position peaked at $541M in Q2 2016. 1,664 funds tracked by Wall St. Rank hold BSX as of Q1 2026.

OrbiMed held 2,382,100 shares of Boston Scientific worth $149M as of Q1 2026.
OrbiMed sold 37,200 Boston Scientific shares in Q1 2026, an estimated $2.98M.
Boston Scientific made up 2.96% of OrbiMed's portfolio in Q1 2026, its #7 holding.
OrbiMed first reported a position in Boston Scientific in Q3 2013 and has held it in 50 quarters since.
OrbiMed's Boston Scientific position peaked at $541M in Q2 2016.
1,664 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.

Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.